About

Publication thumbnail: Identification of Two Tofacitinib Subpopulations with Different Relative Risk Versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance

Identification of Two Tofacitinib Subpopulations with Different Relative Risk Versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance

Publication thumbnail: When to Start Secukinumab Treatment in Patients with Axial Spondyloarthropathy: Before or After Anti-TNFα Treatment?

When to Start Secukinumab Treatment in Patients with Axial Spondyloarthropathy: Before or After Anti-TNFα Treatment?

Author Interview: Shikha Singla

Publication thumbnail: Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients with Active Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients with Active Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study

Publication thumbnail: Efficacy of Secukinumab on Dactylitis in Patients with Active Psoriatic Arthritis from the FUTURE 5 study

Efficacy of Secukinumab on Dactylitis in Patients with Active Psoriatic Arthritis from the FUTURE 5 study

Publication thumbnail: Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies

Publication thumbnail: Sex Differences in the Efficacy, Safety and Persistence of Patients with Psoriatic Arthritis Treated with Tofacitinib:  A Post Hoc Analysis of Phase 3 Trials and Long-Term Extension

Sex Differences in the Efficacy, Safety and Persistence of Patients with Psoriatic Arthritis Treated with Tofacitinib: A Post Hoc Analysis of Phase 3 Trials and Long-Term Extension

Publication thumbnail: Association Between Biological Immunotherapy for Psoriasis  and Time to Incident Inflammatory Arthritis:  A Retrospective Cohort Study

Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study

Publication thumbnail: Efficacy and Safety of Golimumab in Patients with  Non-radiographic Axial Spondyloarthritis:  A Withdrawal and Retreatment Study (GO-BACK)

Efficacy and Safety of Golimumab in Patients with Non-radiographic Axial Spondyloarthritis: A Withdrawal and Retreatment Study (GO-BACK)

Publication thumbnail: Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)

Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)

Publication thumbnail: Enthesitis in Patients with Psoriatic Arthritis Treated with Secukinumab or Adalimumab: a post hoc Analysis of the EXCEED Study

Enthesitis in Patients with Psoriatic Arthritis Treated with Secukinumab or Adalimumab: a post hoc Analysis of the EXCEED Study

AxSpA Podcast: AS Associated MACE & Upadacitinib's Long Term Safety

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

Discussing Rheumatology: April 2023

Publication thumbnail: Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Axial Involvement: Results From Two Phase 3 Studies

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Axial Involvement: Results From Two Phase 3 Studies

Publication thumbnail: Secukinumab Improves Physical Function and Quality of Life and Inhibits Structural Damage in Patients with PsA with Sustained Remission or Low Disease Activity: Results From the 2-year Phase 3 FUTURE 5 Study

Secukinumab Improves Physical Function and Quality of Life and Inhibits Structural Damage in Patients with PsA with Sustained Remission or Low Disease Activity: Results From the 2-year Phase 3 FUTURE 5 Study

Publication thumbnail: A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report

A Patient with Adalimumab-induced Refractory Paradoxical Palmoplantar Pustulosis was Successfully Treated by Ixekizumab: A Case Report

PsA Podcast: Herpes Zoster in JAK Inhibitor Therapies & The APEX Protocol

Discussing Rheumatology: March 2023

Publication thumbnail: Low Rates of Radiographic Progression Associated with Clinical Efficacy Following up to 2 Years of Treatment with Guselkumab: Results From a Phase 3, Randomised, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis

Low Rates of Radiographic Progression Associated with Clinical Efficacy Following up to 2 Years of Treatment with Guselkumab: Results From a Phase 3, Randomised, Double-blind, Placebo-controlled Study of Biologic-naïve Patients with Active Psoriatic Arthritis

Publication thumbnail: Association Between Baseline Cardiovascular Risk and Incidence Rates of Major Adverse Cardiovascular Events and Malignancies in Patients with Psoriatic Arthritis and Psoriasis Receiving Tofacitinib

Association Between Baseline Cardiovascular Risk and Incidence Rates of Major Adverse Cardiovascular Events and Malignancies in Patients with Psoriatic Arthritis and Psoriasis Receiving Tofacitinib

Publication thumbnail: Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data

Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data

Publication thumbnail: Safety Profile of Upadacitinib over 15 000 Patient-years Across Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Atopic Dermatitis

Safety Profile of Upadacitinib over 15 000 Patient-years Across Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Atopic Dermatitis

Publication thumbnail: Impact of NSAIDs on 8-year Cumulative Incidence of Major Cardiovascular Events in Patients with Ankylosing Spondylitis: A Nationwide Study

Impact of NSAIDs on 8-year Cumulative Incidence of Major Cardiovascular Events in Patients with Ankylosing Spondylitis: A Nationwide Study

Publication thumbnail: Malignancy Risk with Tofacitinib versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-Label, Randomised Controlled Oral Surveillance Trial

Malignancy Risk with Tofacitinib versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-Label, Randomised Controlled Oral Surveillance Trial

Publication thumbnail: Safety of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis as used in Clinical Practice: Results from the ARTIS Programme

Safety of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis as used in Clinical Practice: Results from the ARTIS Programme

Publication thumbnail: Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

Discussing Rheumatology: February 2023

Publication thumbnail: Impact of Cardiovascular Risk Enrichment on Incidence of Major Adverse Cardiovascular Events in the Tofacitinib Rheumatoid Arthritis Clinical Programme

Impact of Cardiovascular Risk Enrichment on Incidence of Major Adverse Cardiovascular Events in the Tofacitinib Rheumatoid Arthritis Clinical Programme

Publication thumbnail: Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

Publication thumbnail: Opportunistic Infections Associated with Janus Kinase Inhibitor Treatment for Rheumatoid Arthritis:  A Structured Literature Review

Opportunistic Infections Associated with Janus Kinase Inhibitor Treatment for Rheumatoid Arthritis: A Structured Literature Review

Publication thumbnail: Safety of Guselkumab with and without Prior TNF-α Inhibitor Treatment: Pooled Results Across Four Studies in Patients with Psoriatic Arthritis

Safety of Guselkumab with and without Prior TNF-α Inhibitor Treatment: Pooled Results Across Four Studies in Patients with Psoriatic Arthritis